ConductScience.org, home

Paper25614280

Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials.

Santos RD and 5 others. Arterioscler Thromb Vasc Biol, 2015. Cited by 164 papers, by iCite.

Cite this record

ConductScience Library. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Papers, record 25614280. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25614280

Download JSON
Disease
coronary artery disorder241 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials.
PubMed
Journal
Arterioscler Thromb Vasc Biol
PubMed
Year
2015
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
164
iCite
Relative citation ratio, by iCite
5.23
iCite
Revised in PubMed
2024-12-19
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Santos RDRaul D
2Raal FJFrederick J
3Catapano ALAlberico L
4Witztum JLJoseph L
5Steinhagen-Thiessen EElisabeth
6Tsimikas SSotirios

Source PubMed

Download CSV of authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anticholesteremic AgentsMajor topic
Apolipoprotein B-100Major topic
Hyperlipoproteinemia Type IIMajor topic
Lipoprotein(a)Major topic
Oligodeoxyribonucleotides, AntisenseMajor topic
OligonucleotidesMajor topic
Adult
Aged
Biomarkers
Cardiovascular Diseases
Clinical Trials, Phase III as Topic
Down-Regulation
Female
Humans
Male
Middle Aged
Randomized Controlled Trials as Topic
Risk Assessment
Risk Factors
Treatment Outcome

Source PubMed

Download CSV of topics

Grants10

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P01 HL088093NHLBI NIH HHSUnited StatesP01HL088093PubMed and NIHNIH RePORTER
U54 HL119893NHLBI NIH HHSUnited StatesU54HL119893PubMed and NIHNIH RePORTER
P01-HL088093NHLBI NIH HHSUnited StatesP01HL088093PubMed and NIHNIH RePORTER
U54-HL119893NHLBI NIH HHSUnited StatesU54HL119893PubMed and NIHNIH RePORTER
R01-HL093767NHLBI NIH HHSUnited StatesR01HL093767PubMed and NIHNIH RePORTER
R01-HL119828NHLBI NIH HHSUnited StatesR01HL119828PubMed and NIHNIH RePORTER
R01 HL119828NHLBI NIH HHSUnited StatesR01HL119828PubMed and NIHNIH RePORTER
P01 HL055798NHLBI NIH HHSUnited StatesP01HL055798PubMed and NIHNIH RePORTER
P01-HL055798NHLBI NIH HHSUnited StatesP01HL055798PubMed and NIHNIH RePORTER
R01 HL093767NHLBI NIH HHSUnited StatesR01HL093767PubMed and NIHNIH RePORTER

Download CSV of grants

Trials4

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT00607373Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial HypercholesterolemiaDerived from the trialYesClinicalTrials.gov
NCT00706849Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery DiseaseDerived from the trialYesClinicalTrials.gov
NCT00770146Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic PatientsDerived from the trialYesClinicalTrials.gov
NCT00794664Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on ApheresisDerived from the trialYesClinicalTrials.gov

Download CSV of trials

References67

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
123060426
Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
Circulation2012https://conductscience.org/library/papers/23060426PubMed
222969153Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions.J Lipid Res2012https://conductscience.org/library/papers/22969153PubMed
323065826Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study.Arterioscler Thromb Vasc Biol2012https://conductscience.org/library/papers/23065826PubMed
423152839Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy.PLoS One2012https://conductscience.org/library/papers/23152839PubMed
523041907Emerging therapeutic agents to lower lipoprotein (a) levels.Curr Opin Lipidol2012https://conductscience.org/library/papers/23041907PubMed
623099120In vivo stable-isotope kinetic study suggests intracellular assembly of lipoprotein(a).Atherosclerosis2012https://conductscience.org/library/papers/23099120PubMed
710669652Lipoprotein(a) in homozygous familial hypercholesterolemia.Arterioscler Thromb Vasc Biol2000https://conductscience.org/library/papers/10669652PubMed
811230837Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia.Am J Cardiol2001https://conductscience.org/library/papers/11230837PubMed
912575961Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes.J Am Coll Cardiol2003https://conductscience.org/library/papers/12575961PubMed
1014578310Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions.Clin Chem2003https://conductscience.org/library/papers/14578310PubMed
1114739118Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein(a).Arterioscler Thromb Vasc Biol2004https://conductscience.org/library/papers/14739118PubMed
1215184281Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.Circulation2004https://conductscience.org/library/papers/15184281PubMed
1315353498High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.Circulation2004https://conductscience.org/library/papers/15353498PubMed
142530005HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels.Circulation1989https://conductscience.org/library/papers/2530005PubMed
152139920Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia.N Engl J Med1990https://conductscience.org/library/papers/2139920PubMed
168280186The immediate effect of streptokinase on serum lipoprotein(a) concentration and the effect of myocardial infarction on serum lipoprotein(a), apolipoproteins A1 and B, lipids and C-reactive protein.Atherosclerosis1993https://conductscience.org/library/papers/8280186PubMed
177495281Apolipoprotein(a) deposition in atherosclerotic plaques of cerebral vessels. A potential role for endothelial cells in lesion formation.Am J Pathol1995https://conductscience.org/library/papers/7495281PubMed
189017509Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans.J Lipid Res1996https://conductscience.org/library/papers/9017509PubMed
1923174369Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia.Atherosclerosis2013https://conductscience.org/library/papers/23174369PubMed
2022998429Lipoprotein(a): resurrected by genetics.J Intern Med2013https://conductscience.org/library/papers/22998429PubMed

See all 67 referencesDownload CSV of references

Cited by88

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 164 citations.

PMIDTitleJournalYearIn PapersSource
42973626Advances in therapeutic oligonucleotide conjugates.AAPS Open2026https://conductscience.org/library/papers/42973626PubMed
42133095Targeting PCSK9, APOB, and CETP at the Transcriptome Level by hsa-miR-30b-3p Reduces LDL-Associated Protein in Huh-7 Cells.Mol Biol Rep2026https://conductscience.org/library/papers/42133095PubMed
42032080Tissue-selective COPII modulator SEC16B aggravates cardiovascular disease by promoting lipid export.EMBO J2026https://conductscience.org/library/papers/42032080PubMed
41803448Advances in computational prediction of RNA-small molecule binding affinity.J Comput Aided Mol Des2026https://conductscience.org/library/papers/41803448PubMed
41660526A Position Paper on Lipoprotein(a) From the Lipoprotein(a) Task Force of the Korean Society of Lipid and Atherosclerosis: Current Evidence, Clinical Applications, and Future Directions.J Lipid Atheroscler2026https://conductscience.org/library/papers/41660526PubMed
41621836RNA-Based Therapies for Inherited Metabolic Disorders.J Inherit Metab Dis2026https://conductscience.org/library/papers/41621836PubMed
41560299A Position Paper on Lipoprotein(a) From the Lipoprotein(a) Task Force of the Korean Society of Lipid and Atherosclerosis: Current Evidence, Clinical Applications, and Future Directions.Korean Circ J2026https://conductscience.org/library/papers/41560299PubMed
41346702The efficacy of oligonucleotide-based gene therapeutics in gene silencing.Theranostics2026https://conductscience.org/library/papers/41346702PubMed
40968429Lepodisiran: Effects on Lipoprotein(a) and Cardiovascular Outcomes in Adults with Elevated Lp(a).Cardiovasc Hematol Disord Drug Targets2026https://conductscience.org/library/papers/40968429PubMed
40654252Role of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease in South Asian Individuals.J Am Heart Assoc2025https://conductscience.org/library/papers/40654252PubMed
40487670Inhaled non-viral delivery systems for RNA therapeutics.Acta Pharm Sin B2025https://conductscience.org/library/papers/40487670PubMed
40026530Could the Hemodynamic Progression of Aortic Valve Stenosis be Slowed Pharmacologically? The Unsolved Dilemma.Rev Cardiovasc Med2025https://conductscience.org/library/papers/40026530PubMed
39934773Lipid-lowering drug targets associated with risk of respiratory disease: a Mendelian randomization study.BMC Pulm Med2025https://conductscience.org/library/papers/39934773PubMed
39756980New Approaches to Lipoproteins for the Prevention of Cardiovascular Events.J Atheroscler Thromb2025https://conductscience.org/library/papers/39756980PubMed
39598201The Impact of Diet on Lipoprotein(a) Levels.Life (Basel)2024https://conductscience.org/library/papers/39598201PubMed
39476283Antisense Oligonucleotides in Dyslipidemia Management: A Review of Clinical Trials.High Blood Press Cardiovasc Prev2025https://conductscience.org/library/papers/39476283PubMed
39385797Novel Targets and Strategies Addressing Residual Cardiovascular Risk in Post-acute Coronary Syndromes Patients.Transl Med UniSa2024https://conductscience.org/library/papers/39385797PubMed
39302109Lipoprotein(a) and cardiovascular disease.Biochem J2024https://conductscience.org/library/papers/39302109PubMed
38878139Lipoprotein (a)-Related Inflammatory Imbalance: A Novel Horizon for the Development of Atherosclerosis.Curr Atheroscler Rep2024https://conductscience.org/library/papers/38878139PubMed
38542510Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?Int J Mol Sci2024https://conductscience.org/library/papers/38542510PubMed

See all 88 cited byDownload CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
APOB338PubTator's text mininghttps://conductscience.org/library/genes/338NCBI Gene
IL63569PubTator's text mininghttps://conductscience.org/library/genes/3569NCBI Gene
LDLR3949PubTator's text mininghttps://conductscience.org/library/genes/3949NCBI Gene
LPA4018PubTator's text mininghttps://conductscience.org/library/genes/4018NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
MIPOMERSENCHEMBL2219536Derived from the trial4https://conductscience.org/library/drugs/CHEMBL2219536

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/25614280

GET https://conductscience.org/api/papers/v1/25614280/references?page=2